Bolt Biotherapeutics, Inc. (BOLT) is a clinical-stage immuno-oncology company pioneering the development of tumor-targeted therapies. The core platform of Bolt Biotherapeutics is its Boltbody™ Immune-Stimulating Antibody Conjugate (ISAC). Boltbody™ ISACs are designed to harness the power of the immune system by targeting tumor cells and creating an inflammatory tumor microenvironment to ignite the immune system and enable it to destroy and attack cancerous cells.
The company was founded in 2015 by Dr. Ed Engleman, a renowned scientist and inventor of the first FDA-approved therapeutic cancer vaccine, Provenge. The company is based in Redwood City, California, and it’s committed to discovering and developing innovative, first-in-class therapies which can improve the lives of patients suffering from cancer all around the world.
Bolt Biotherapeutics' lead program, BDC-1001, is a HER2-targeted Boltbody™ ISAC, which is currently in a Phase 1/2 clinical trial for patients with HER2-expressing solid tumors. This adventure represents a promising advance in the field of immunotherapy – a branch of medicine that uses the body's own immune system to help fight cancer – a category that includes potentially revolutionary treatments like CAR-T cell therapy.
In addition to BDC-1001, Bolt Biotherapeutics is also progressing multiple Boltbody™ ISAC programs aimed at cellular targets expressed across a wide range of solid tumors. The brilliance in the Boltbody™ ISAC approach lies in its ability to engage the immune system's innate response by converting cold tumors to hot, thereby triggering a powerful, systemic immune response.
This company is powered by a team of seasoned drug developers and scientists who are passionate about leveraging immunology principles to develop the next wave of cancer therapies. They strive for a culture of creativity, intellectual curiosity, and a focus on improving patient outcomes.
In summary, Bolt Biotherapeutics, Inc. is a cutting-edge life sciences company, committed to unlocking the power of the immune system to fight cancer. The company's innovative Boltbody™ ISAC platform paves the way for next-generation treatments, looking to revolutionize cancer therapies and improve patient survival rates.
Income statement
Balance sheet statement
Cash flow statement
Current assets / Current liabilities
Equity / Debt / Cash
Dividends
Bolt Biotherapeutics reported its second-quarter 2026 financial results, highlighting ongoing progress in the BDC-4182 Phase 1/2 study for gastric and gastroesophageal cancer, with initial clinical data expected in Q3 2026. The company's cash balance of $18.1 million as of June 30, 2026, is anticipated to fund operations into Q1 2027. They also provided financial details, including a decrease in R&D and G&A expenses due to restructuring.
Bolt Biotherapeutics Inc. (BOLT) reported a second-quarter loss of $7.7 million, or $4.57 per share. The company generated $5,000 in revenue during the period. Bolt Biotherapeutics shares closed at $4.02 on Tuesday, down from $5.63 a year ago.
Bolt Biotherapeutics, Inc. (BOLT) reported a Q2 loss of $4.57 per share, significantly missing the Zacks Consensus Estimate of a $2.97 loss and last year's $4.46 loss. The company also missed revenue estimates, posting $0.01 million against an expectation of $3.03 million. Despite recent underperformance, the stock holds a Zacks Rank #3 (Hold), suggesting it will perform in line with the market.